Molecular Cell, Volume 41

Supplemental Information

Disorder Targets Misorder in Nuclear Quality

Control Degradation: A Disordered Ubiquitin Ligase

Directly Recognizes Its Misfolded Substrates

Joel C. Rosenbaum, Eric K. Fredrickson, Michelle L. Oeser, Carrie M. Garrett-Engele, Melissa N. Locke, Lauren A. Richardson, Zara W. Nelson, Elizabeth D. Hetrick, Thomas I. Milac, Daniel E. Gottschling, and Richard G. Gardner



Figure S1: Predicted disorder of San1 homologs. Disorder prediction of the indicated San1 homologs using PONDR (<u>http://www.pondr.com/</u>). Predicted disordered regions have a positive PONDR score by the VL-XT algorithm (yellow).



Figure S2. Steady-State Levels of San1 Deletion Mutants Are Similar. Whole cell lysates were analyzed from cells expressing GBD-San1 with the indicated San1 deletion. Anti-HSV antibodies were used to detect each GBD-San1 protein.

Figure S3: Toxicity of GAD Fusion Proteins. Wild-type or $san1\Delta$ cells expressing the indicated GAD fusion, with or without an NLS, were spotted in 10-fold serial dilutions onto media containing glucose or galactose. Those GAD fusions whose degradation was primarily dependent upon San1 are grouped in the left column. Those GAD fusions whose degradation was slightly dependent upon San1 are grouped in the right column. Arrows indicate the GAD fusions that confer some observable growth defect.

Partially depende

õ

0000

Primarily dependent on San1

			Not Induced	Induced		Not Induced
→	Ura4 ^{90-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Tdh3 ^{94-end} –	+NLS, SAN1
→	Pdc1 ^{171-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Reverse 2 –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆
	Pnc1 ^{13-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆		● ● ● ● ♥ ♥ < ● ● ● ● ● ♥ ♥ ● ● ● ● ● ♥ ♥	Reverse 3 –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆
→	Sed1 ^{5-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Scw4 ^{120-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆
	Reverse 1 –	+NLS, <i>SAN1</i> +NLS, <i>san1</i> ∆ -NLS, <i>SAN1</i> -NLS, <i>san1</i> ∆	●●●● ●●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●	●●●●◎袋·×` ●●●●◎袋·*` ●●●●●◎袋·*`	Tdh2 ^{70-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆
→	Cap2 ¹⁶⁻²⁰² –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆		● ● ● ● ● ◎ ☆ ↓ ● ● ● ● ◎ ☆ [↓] ● ● ● ● ◎ ☆ [↓]	Yol155c ^{813-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆
→	Pro3 ^{28-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Hom2 ^{193-end} –	+NLS, SAN1 +NLS, san1Δ -NLS, SAN1 -NLS, san1Δ
→	Tos1 ^{36-end} -	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Tdh1 ^{107-end} –	+NLS, SAN1 +NLS, san1Δ -NLS, SAN1 -NLS, san1Δ
→	IIv2 ^{44-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Reverse 4 -	+NLS, SAN1 +NLS, san1Δ -NLS, SAN1 -NLS, san1Δ
→	Ses1 ^{216-end} –	+NLS, <i>SAN1</i> +NLS, <i>san1</i> ∆ -NLS, <i>SAN1</i> -NLS, <i>san1</i> ∆			Reverse 5 –	+NLS, SAN1 +NLS, san1Δ -NLS, SAN1 -NLS, san1Δ
	Ntf2 ^{19-end} -	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆	●●●● ●● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ●		Reverse 6 –	+NLS, SAN1 +NLS, san1Δ -NLS, SAN1 -NLS, san1Δ
→	Tef2 ^{190-end} -	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆			Mot2 ^{+17-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆
→	Bgl2 ^{20-end} –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆				
→	Upc2 ⁴²⁰⁻⁸¹⁷ –	+NLS, SAN1 +NLS, san1∆ -NLS, SAN1 -NLS, san1∆		● ● ● @ ☆ ● @ ● ● ● @ ☆ ← ● ● ● @ ☆ →		



Figure S4. GAD Fusion Proteins Are San1 Substrates. (A) Degradation assays of GAL4AD fusions with the GAL4AD NLS intact. Cycloheximide-chase assays of cells expressing the indicated GAD fusion were performed to assess stability in the presence or absence of *SAN1*. Time after cycloheximide addition is indicated above each lane. Anti-GAD antibodies were used to detect each GAD fusion. Those GAD fusions whose degradation was primarily dependent upon San1 are grouped in the left column. Those GAD fusions whose degradation was slightly dependent upon San1 are grouped in the right column. (B) Degradation assays of the same fusions with the NLS removed. (C) San1-mediated degradation does not require Asc1, Cnm67, or Nif3. Cycloheximide-chase assays of cells expressing the indicated GAD fusion were performed to assess stability in the presence or absence of *SAN1*, *ASC1*, *CNM67*, or *NIF3*.